Drugs / Soquelitinib
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06345404 | Apr 2024 → Jan 2026 | atopic eczema | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03952078 | May 2019 → Apr 2026 overdue | T-cell non-Hodgkin lymphoma | Corvus Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07441395 | Feb 2026 → Jun 2027 expected | atopic eczema | Corvus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06730126 | Mar 2025 → Dec 2026 expected | autoimmune lymphoproliferative syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06561048 | Oct 2024 → Nov 2027 expected | Nodal T-follicular helper cell lymphoma, follicular type, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Corvus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Soquelitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06561048 ↗ |
| Known as | CP-000596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CP-596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CPI-000818 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CPI-596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CPI-818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03952078 ↗ |
| Action | Inhibit | “CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor” NCT03952078 ↗ |
| Modality | Small molecule | — CHEMBL5817577 ↗ |
| Route | Oral | “Participants will receive CPI-818 capsule, orally, twice per day” NCT03952078 ↗ |
| Target | ITK | “CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor” NCT03952078 ↗ |